Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Pope Leo in Rome hospital for surgery

Leo has been unusually candid for a pontiff about his health issues, disclosing the surgery to thousands of people in St. Peter's Square.

Pope Leo XIV is set to undergo surgery on Tuesday at Rome's Gemelli hospital to remove a nodule from his lung, according to the Vatican. The health check is aimed at determining if the nodule is cancerous. The 71-year-old pontiff, speaking to thousands of worshippers during a prayer service on Sunday, marked a significant increase in transparency regarding his health compared to previous popes.

In the past, the Vatican frequently faced criticism for providing confusing or vague information about the health of its leaders. The surgery will require the pontiff to be under general anesthesia and will necessitate a week-long hospital stay. All of Leo's engagements have been canceled until October 20, but he is still expected to attend a planned trip to South America in November.

Oncologists state that such a procedure is typically performed to ascertain whether a lump is malignant, but in Leo's case, early detection offers an excellent prognosis.

Written by urgent.news from DW News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at dw.com →

More in Health & Medicine

Nigeria: AMR - Livestock Uses More Antibiotics Than Human Health Sector - Pate

[Premium Times] Mr Pate said antimicrobial resistance could move between humans, animals and the environment, emphasising the need for collaboration across sectors.

  • Livestock sector uses more antibiotics than human health sector in Nigeria.
  • Coordinating Minister Muhammad Pate stresses responsible antibiotic use.
  • Collaboration across sectors needed to combat antimicrobial resistance.

T MAXIMUM secures US FDA clearance for Phase 2 CAR T trial

Biotechnology firm T MAXIMUM received regulatory clearance from the US Food and Drug Administration to initiate a Phase 2 trial of MT027 for secondary brain metastases

  • FDA clears T-MAXIMUM to start Phase 2 CAR T trial for MT027.
  • MT027 targets B7-H3 for recurrent glioblastoma and universal CAR-T therapy.
  • T-MAXIMUM holds Orphan Drug and Fast Track Designations for MT027.

More from Tuesday 13 October →